<sup>161</sup>Tb Radioimmunotherapy as a Treatment for CD30-Positive Lymphomas

Elisa Rioja-Blanco(Paul Scherrer Institute), Martin Béhé(Paul Scherrer Institute), Pascal V. Grundler(Paul Scherrer Institute), Michal Grzmil(Paul Scherrer Institute), Roger Schibli(Paul Scherrer Institute), Nicole Bertschi(University of Bern), Peter Bernhardt(Sahlgrenska University Hospital), Tanja Chiorazzo(Paul Scherrer Institute), Urban Novak(University of Bern), Nicholas P. van der Meulen(Paul Scherrer Institute), Yara Banz(Beth Israel Deaconess Medical Center), Christoph Schlapbach(University of Bern)
Journal of Nuclear Medicine
June 1, 2025
10.2967/jnumed.124.268805
Cited by 8

Related Papers

Heterochromatin Protein 1 Secures Survival and Transmission of Malaria Parasites
|Cell Host & Microbe|2014|322
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network
|The Lancet|2024|135
Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy
|EJNMMI Radiopharmacy and Chemistry|2019|107
Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A–induced hepatitis
|Hepatology|2008|90
Deletion of Cd39 on Natural Killer Cells Attenuates Hepatic Ischemia/Reperfusion Injury in Mice
|Hepatology|2009|76